New blood test offers early detection of neurodegenerative disorder

The Food and Drug Administration (FDA) recently approved a new tool in the fight against Alzheimer’s disease — a blood test that detects plaques known to be linked to the disease.

The test, developed by the Japanese firm Fujirebio Diagnostics, is called the Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, and works by detecting and measuring amyloid and tau, two forms of amyloid-beta proteins in the blood, which form plaques in the brains of Alzheimer’s patients.

Why it matters

Trump administration halts mRNA vaccine research

The Trump administration has announced it will “wind down” federal mRNA vaccine research and development, marking a shift away from the technology that powered COVID-19 vaccination efforts during the pandemic.

U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr said the decision follows a review of scientific data, expert input and safety concerns.

Why it matters

Debate bubbles up as a popular drink changes ingredients

Coca-Cola announced this week it will bring a limited run of Coca-Cola Classic made with cane sugar to U.S. shelves — a move that quickly drew praise from President Donald Trump, who took credit for the change in a post on Truth Social.

Read more

Lynch: Allegations of Kentucky group’s organ donation misconduct warranted federal review

Historically, the U.S. Health Resources and Services Administration (HRSA) did not receive complete, consistent and, at times, accurate information regarding patient safety complaints and concerns raised by Organ Procurement and Transplantation Network (OPTN) members and other stakeholders. Passage of the Securing the OPTN Act enabled HRSA to begin its modernization efforts to separate OPTN Board functions from OPTN contractor functions. 

Read more